Barclays raised the firm’s price target on West Pharmaceutical (WST) to $275 from $260 and keeps an Equal Weight rating on the shares as part of a Q3 preview for the life science tools and diagnostics group. The firm views the companies’ end markets as stable with improvements likely going forward. In addition, investment sentiment “feels bottomed” as share valuations have come down, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- Strong Market Position and Growth Potential Justify Buy Rating for West Pharmaceutical Services
- West Pharmaceutical initiated with a Buy at Rothschild & Co Redburn
- West Pharmaceutical Announces Departure of Senior VP
- AI Analyst Is Bullish on These 3 “Strong Buy” Healthcare Stocks, 9/2/25